Clinical Trials Logo

Stiff-Person Syndrome clinical trials

View clinical trials related to Stiff-Person Syndrome.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02282514 Terminated - Clinical trials for Stiff-Person Syndrome

Stem Cell Transplantation for Stiff Person Syndrome (SPS)

SPS
Start date: October 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Non-myeloablative regimens (as the investigators use herein) are designed to maximally suppress the immune system without destruction of the bone marrow stem cell compartment. When using a non-myeloablative regimen recovery occurs without infusion of stem cells and the stem cells are autologous. While not necessary for recovery, stem cell infusion may shorten the interval of neutropenia and attendant complications. Thus in reality there is no transplant only an autologous supportive blood product. Based on our encouraging results of non-myeloablative hematopoietic stem cell transplantation, for patients with multiple sclerosis and chronic inflammatory demyelinating polyneuropathy, the investigators will investigate the role of non-myeloablative hematopoietic stem cell transplantation for patients with SPS who require assistance to ambulate.

NCT ID: NCT01476514 Terminated - Hyperekplexia Clinical Trials

Effects of Mutations of the Glycine Gene Associated With Hyperekplexia on Central Pain Processing

Start date: October 2011
Phase: N/A
Study type: Interventional

Mutations in genes affecting pain transmission start to be known, the investigators are investigating a mutation in a glycine channel, which has an influence on pain modulation. Pain modulation is the ability of the central nervous system to enhance or diminish the sensation of pain. The investigators therefore will test patients and healthy volunteers with quantitative sensory tests, basically determining the point at which a stimulation just starts to induce pain. These tests are reliable and permit a direct comparison between healthy volunteers and patients with the affected glycine gene.